Intrexon | XON - 销售和管理费用





销售和管理费用 更改 日
Agenus USD 10.56M 13.04M 2025-12
Alaunos Therapeutics USD 447K 138K 2026-03
Amgen USD 1.58B 354M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 328.1M 62.31M 2026-03
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 54.08M 4.33M 2026-03
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Thermo Fisher Scientific USD 1.8B 179M 2026-03
Veracyte USD 50.84M 7.53M 2026-03
Xencor USD 82.12M 65.08M 2026-03